GlassScriptPhysician profile
Kimberly M Connally
NPI 1487856092
$12,568.77
in general payments reported to CMS, 2019-2025
28 companies · $4,411 in 2025
The $4,411 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $972 · 2023: $1,812 · 2024: $4,455 · 2025: $4,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,037 · Consulting Fee: $2,280 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,036.69 |
| Consulting Fee | $2,280.00 |
| Education | $360.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,532.21 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,328.86 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,215.10 | 2021-2025 | |
| Amgen INC. | $1,158.11 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $980.22 | 2022-2025 | |
| Lilly USA, LLC | $470.28 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $411.86 | 2023-2025 | Tremfya |
| Genzyme Corporation | $409.37 | 2021-2025 | |
| Galderma Laboratories, L.P. | $409.22 | 2024-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $367.55 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $356.16 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $345.62 | 2023-2025 | Winlevi, Odomzo, Blu-U |
| Dermavant Sciences, INC. | $340.06 | 2023-2024 | Vtama |
| Incyte Corporation | $326.16 | 2022-2025 | Opzelura |
| Pfizer INC. | $211.59 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $163.95 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $158.37 | 2025 | Adstiladrin |
| Leo Pharma INC. | $95.30 | 2023-2025 | Adbry, Anzupgo |
| Merck Sharp & Dohme LLC | $75.79 | 2023-2024 | Keytruda |
| Helsinn Therapeutics (U.S.), INC. | $40.11 | 2023-2024 | Valchlor |
| Mayne Pharma Commercial LLC | $34.93 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.66 | 2025 | Targretin, Duobrii, Siliq |
| Verrica Pharmaceuticals INC. | $22.45 | 2025 | Ycanth |
| Organon LLC | $22.01 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.17 | 2024 | Spevigo |
| Genentech USA, INC. | $20.96 | 2024 | Erivedge |
| Fresenius Kabi USA, LLC | $14.35 | 2024 | Idacio |
| Janssen Pharmaceuticals, INC | $14.35 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Connally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.